Une dose du vaccin contre le HPV suffirait-elle ?

PARIS – 8 Mai 2024 –

Une recherche prometteuse suggère un changement potentiel dans la vaccination contre le HPV. Une étude majeure a constaté qu’une seule dose du vaccin contre le HPV pourrait être aussi efficace que les deux ou trois doses recommandées, protégeant ainsi contre l’infection et les problèmes de santé associés, notamment le cancer du col de l’utérus. Cette découverte pourrait simplifier les calendriers de vaccination et améliorer l’accès mondial, comme le confirment les experts. Pour en savoir plus sur les implications de cette avancée, lisez la suite.

Here’s a rewritten version of the article, focusing on clarity, conciseness, and readability:

Headline: Could One HPV Vaccine Dose Be Enough? New Research Sparks Optimism

Summary: A recent large-scale study indicates that a single dose of the HPV vaccine may provide sufficient protection against HPV infection and related cancers, like cervical cancer. This finding could simplify vaccination schedules and improve global access.

Article:

Exciting new research suggests that the standard HPV vaccination protocol might be undergoing a meaningful change. A large study has found that a single dose of the HPV vaccine could be just as effective as the currently recommended two or three doses in protecting against HPV (human papillomavirus) and related health problems,including cervical cancer.

When the HPV vaccine first became available in 2006, the recommended schedule was three doses. This involved an initial shot, a second dose one to two months later, and a final dose six months after the first. This multi-dose schedule presented challenges for some,leading to incomplete vaccination rates.Over time, research began to question the necessity of three doses. Studies indicated that two doses offered comparable protection, especially in younger individuals with robust immune responses. In 2016, the Advisory Committee on Immunization Practices (ACIP) updated it’s guidelines, recommending two doses for those starting the vaccination series before age 15.

Now,the ESCUDDO trial,a study involving over 20,000 girls aged 12-15 in costa Rica,is adding further evidence to the “less is more” argument. The study compared the effectiveness of one dose versus two doses of two different HPV vaccines: Cervarix (protecting against two high-risk HPV types) and Gardasil 9 (protecting against nine HPV types).

The results showed no significant difference in HPV infection rates or antibody production between the girls who received one dose and those who received two doses of either vaccine. Researchers also compared these results to a group of unvaccinated women and found that vaccination, regardless of whether it was one or two doses, substantially reduced potential HPV cases.

These findings align with previous research. A 2016 study from India showed that a single dose of an earlier version of Gardasil offered adequate protection.Similarly, a trial in Kenya found that one dose of either Gardasil 9 or Cervarix was highly effective (98%) in preventing HPV 16/18 infection for up to three years after vaccination.

What This Means:

A shift to a single-dose HPV vaccine regimen could have several positive impacts:

Increased Vaccination Rates: Simplifying the schedule could remove barriers like transportation and time constraints, leading to higher vaccination rates.
Improved Global access: A single-dose approach would make large-scale vaccination programs more feasible and affordable, especially in resource-limited countries.The ACIP discussed the possibility of a one-dose HPV vaccine schedule at its April meeting and may revise its recommendations in June. However, political factors and funding limitations could influence the decision.

the growing body of evidence supporting the effectiveness of a single-dose HPV vaccine is promising. It could revolutionize HPV prevention efforts, making vaccination more accessible and ultimately reducing the burden of HPV-related diseases worldwide.